Study participants and design
stroke, CKD, hypertensive, Stroke
STROKE, STROKE
This was a post hoc analysis of 935 hypertensive adults from the China Stroke Primary Prevention Trial (CSPPT), a folic acid intervention trial to prevent stroke. The study design and major results of the CSPPT (registered at clinicaltrials.gov as NCT00794885) (A total of 20,702 eligible participants were randomly assigned, in a 1:1 ratio, to 1 of 2 treatments: The renal substudy of the CSPPT suggested that folic acid treatment can significantly delay the progression of CKD by 55% among hypertensive patients with mild to moderate CKD (The parent study (CSPPT) was approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China (FWA assurance number: FWA00001263). All participants provided written, informed consent.